Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
673
Employees673
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
673
Employees673

CYTK Key Statistics

Market cap
7.81B
Market cap7.81B
Price-Earnings ratio
-9.30
Price-Earnings ratio-9.30
Dividend yield
—
Dividend yield—
Average volume
2.68M
Average volume2.68M
High today
$57.05
High today$57.05
Low today
$55.15
Low today$55.15
Open price
$56.19
Open price$56.19
Volume
1.01M
Volume1.01M
52 Week high
$88.31
52 Week high$88.31
52 Week low
$53.55
52 Week low$53.55

Stock Snapshot

The current Cytokinetics(CYTK) stock price is $56.13, with a market capitalization of 7.81B. The stock trades at a price-to-earnings (P/E) ratio of -9.30.

On 2026-11-15, Cytokinetics(CYTK) stock traded between a low of $55.15 and a high of $57.05. Shares are currently priced at $56.13, which is +1.8% above the low and -1.6% below the high.

Cytokinetics(CYTK) shares are trading with a volume of 1.01M, against a daily average of 2.68M.

During the past year, Cytokinetics(CYTK) stock moved between $53.55 at its lowest and $88.31 at its peak.

During the past year, Cytokinetics(CYTK) stock moved between $53.55 at its lowest and $88.31 at its peak.

CYTK News

TipRanks 24h
Cytokinetics Earnings Call Shows Strong MYQORZO Momentum

Cytokinetics ((CYTK)) has held its Q3 earnings call. Read on for the main highlights of the call. Cytokinetics’ latest earnings call carried a strongly positiv...

Simply Wall St 2d
Does New Aficamten Data Change The Bull Case For Cytokinetics Stock?

Cytokinetics recently reported Q3 2026 results, with revenue of US$47.56 million and a reported loss of US$190.07 million, and presented new aficamten data in h...

Does New Aficamten Data Change The Bull Case For Cytokinetics Stock?
Simply Wall St 4d
Is Cytokinetics Undervalued On New Aficamten Data?

Cytokinetics (CYTK) is back in focus after new aficamten data presented at the Hypertrophic Cardiomyopathy Medical Society and American Heart Association Scient...

Is Cytokinetics Undervalued On New Aficamten Data?

Analyst ratings

91%

of 23 ratings
Buy
91.3%
Hold
8.7%
Sell
0%

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.